HeraMED Limited Completes $3.1 Million Capital Raise to Drive Growth and Expansion

Highlights:

• Successful Capital Raise: HeraMED Limited (ASX: HMD) completed a $3.1 million private placement at 1.7 cents per share, representing a ~19% discount to the 15-day VWAP, aimed at accelerating growth and expansion.
• Funding Allocation: The proceeds will support the commercial deployment and integration of the HeraCARE platform into health systems and clinics across the U.S., Australia, and Europe, enhancing access to maternity care.
• Strategic Future Plans: The funds will also be utilized for evidence-based research, strategic partnerships, and executing HeraMED's Four-Point Strategic Plan, positioning the company for significant impact in women's health.

Successful $3.1 Million Placement

HeraMED Limited (ASX: HMD), a leader in digital health technology focused on transforming maternity care, has successfully completed a $3.1 million private placement to sophisticated and professional investors. The capital raise, conducted in two tranches, was completed at 1.7 cents per share, representing a ~19% discount to the 15-day VWAP of 2.1 cents at the time of writing. The funds will be utilized to accelerate the company’s commercial deployments and integration of its HeraCARE platform into large health systems and clinics across the U.S., Australia, and Europe.

Purpose of the Capital Raise

The $3.1 million raised will primarily support the company’s expansion strategy, focusing on the commercial rollouts of HeraCARE, a digital maternity care platform. This includes ongoing pilots and integrations into major health systems and private clinics. The capital will also be used to fund strategic partnerships, evidence-based research, and operational efforts to enhance women’s health globally.

CEO Anoushka Gungadin expressed her optimism regarding the future, stating, "We are delighted to secure this investment, which showcases strong confidence in HeraMED’s vision and solutions for maternity care. This funding will help us execute our Four-Point Strategic Plan, furthering our reach and impact in the key markets we are targeting.”

Breakdown of the Placement

The capital raise will be conducted in two tranches. The first tranche, under ASX Listing Rule 7.1 and 7.1A, will issue 154,312,453 shares, raising approximately $2.623 million. The second tranche, worth $476,688, will issue 28,040,471 shares and is subject to shareholder approval at an EGM in December 2024.

HeraMED is well-positioned to continue its growth trajectory, with the funds enabling the company to capitalize on new opportunities and revolutionize maternity care globally.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com